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doi:10.1016/j.ejvs.2009.06.022Abstract A 37-year-old male was treated with 9 ml of 3% polidocanol foam, and he immedi-
ately reported photopsiae lasting a few minutes, though without migraine. Two hours after
sclerotherapy, the patient developed speech disturbance for a few minutes. A pathological
examination revealed nothing except a patent foramen ovale (PFO). Given the contrast
between the high prevalence of PFO in general population and the extremely low incidence
of neurological deficits after foam sclerotherapy, these deficits may only arise due to
as-yet-unknown aetiology.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Case Report
We performed a duplex ultrasound-guided foam scle-
rotherapy with 3% polidocanol and 9 ml foam volume in
a 37-year-old male patient with recurrent varicosity of the
left great saphenous vein and a truncal varicosity of the left
small saphenous vein (both in stage C4EpAsPr). The foam
was produced using DSS (double syringe system) methodnn, Member of the Advisory
ology (DGP) and the Consor-
mann & Partners Phlebology
burg, Germany.
de (K. Hartmann).
reiburg.de
ty for Vascular Surgery. Publishewith a polidocanol-to-air ratio of 1:4. The foam was
injected within 10 s into the varicosity of the left leg.
During injection, the patient was held supine on an
electrically operated tilt table. Spreading of foam in the
thigh and calf was guided by duplex sonography, and on
reaching the saphenofemoral junction, the patient’s
position was changed for 2 min to 20 head-down position.
Hereafter, the patient was again held for 3 min in a hori-
zontal resting position.
Immediately following foam injection the patient
reported photopsiae for a few minutes. Thereafter, he
recovered and was able to follow the recommended
movement programme. Class II thigh compression stocking
was recommended throughout the day for a period of 2
weeks.d by Elsevier Ltd. All rights reserved.
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speech disturbance for 5e7 min. There were no other signs
or symptoms. He had no history of other significant illness.
Neurological examination, cranial magnetic resonance
(MR scan), electrocardiography (ECG) and thrombophilia
findings were unremarkable.
Multiplanar trans-oesophageal echocardiography (TEE)
revealed a persistent foramen ovale.
Intravenous administration of a contrast agent that does
not pass the pulmonary circulation resulted in four and 10
HITS (high-intensity transient signals) without and with the
Valsalva manoeuvre, respectively. This indicates the pres-
ence of a slight right-to-left shunt during the Valsalva
manoeuvre.
Discussion
The report by Forlee et al. on the occurrence of an
ischaemic stroke following foam sclerotherapy1 led to
renewed debate about the safety of foam sclerotherapy.
Neurological complications, including visual disturbances
and migraine attacks, have been reported after foam
sclerotherapy but are rare, occurring in 1% or less of
patients.2 The visual disturbances were described as ocular
migraine and are said to be due to a vasospastic reaction to
polidocanol rather than to the presence of air bubbles
in the sclerosant, since they occur with both liquid and
foam sclerosants.3 It seems unlikely that an episode of
vasospasm would cause a brief period of hypoperfusion of
the speech centre only after considerable delay. The visual
disturbances after foam sclerotherapy could, however, be
a warning sign of potential neurological deficits. If a patient
reports these disturbances, he/she should be asked to
remain at the clinic for a while or the treating doctor should
be contactable by the patient at all times. Hospitalisation is
unnecessary as this condition occurs very rarely.
Air bubble embolism can also cause transient symptoms,
as has been observed in divers after surfacing.4 Because the
pressure gradient between the right and left atrium is small
in most patients with PFO, the air bubbles can pass into the
left atrium only when the pressure in the right atrium is
increased (e.g., as a result of a Valsalva manoeuvre). The
actual effects of these air bubbles are not yet known. The
delayed onset of neurological symptoms in our patient
could be because, over a period of 2 h, the air bubbles
might have enhanced the vasospasm induced by polidoca-
nol and thereby caused a brief period of reduced arterial
perfusion, resulting in the phonemic paraphasia. The airbubbles associated with foam sclerotherapy would thus be
acting as a source of paradoxical embolism.
Further, a wash-out of coagulation products from the
lower leg after sclerotherapy cannot be excluded, as Van der
Plas states in his ‘‘Letter to the editor’’ in 1994, indicating
that cellular debris or sludge following sclerotherapy could
cause neurological deficits.5 However, more questions arise:
Does sclerotherapy result in the release of serotonin from
lysed platelets causing a migraine-like episode? Could plas-
minogen activator inhibitor-1 (PAI-1) be involved?
Given the contrast between the high prevalence of PFO
in general population (up to 30%)6 and the extremely low
incidence of neurological deficits2 after thousands of foam
sclerotherapy treatments daily worldwide, these deficits
might arise only if another, yet unknown, factor is present.
In summary, transient visual disturbances and other
neurological deficits such as phonemic paraphasia can
occur after foam sclerotherapy. The reported deficits have
disappeared relatively rapidly. Patients should be advised
about the occurrences of such transient events. Awareness
of these facts could obviate the need for expensive inves-
tigations at a later stage and spare the patient from
unnecessary anticoagulant therapy. As reported by Bush
et al.,7 hyperbaric oxygen therapy, as used in diving acci-
dents, may be beneficial in the event of a prolonged
neurological deficit occurring after foam sclerotherapy. No
definite cause of these very rare neurological deficits has
been established to date; however, PFO should be regarded
as a risk factor.
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